GermanyGermany

Germany’s biotech sector grows despite financial crisis

08.05.2009

Berlin – Despite the financial crisis, the German biotech sector has grown moderately in 2008: turnover was again above EUR2bn (+9%) and expenditure for R&D rose above EUR1bn (+1.1%). While the number of dedicated biotech companies, remained about the same at 501, there was a slight increase in the number of employees. These are the main results of the company survey conducted by the information platform biotechnologie.de on behalf of the Federal Ministry of Education and Research (BMBF). The "Biotechnology Company Survey 2009" was officially introduced on May 6th. The data of this comprehensive annual survey were collected along the guidelines of the Organisation for Economic Co-operation and Development (OECD) and present an overview of the German biotech landscape.
Peter Heinrich, spokesman of the BIO Germany management board, emphasised, that in light of the current situation, by international comparison the German biotech sector is still looking relatively good. In the next three years, the industry will need at least one billion euros of equity to follow through with projects currently in company pipelines, finance innovative start-ups, and not be left behind internationally. "We welcome the Federal Ministry of Finance´s initiative to take back parts of the business tax reform", said Peter Heinrich.
The consultancy Ernst&Young released the results of their own assessment of the biotech sector at the same time as biotechnologie.de. The "Biotechnology-Report 2009" confirms the trends elucidated by biotechnologie.de regarding turnover and the number of employees. However, Ernst&Young only includes about 400 companies in their survey due to a non-OECD biotechnology definition. According to the report, the number of candidates in drug development from German biotech companies has slightly increased from 303 to 308. There are some more drug candidates, 139, in clinical trials Phases I to III as in the previous year with 129. Currently, there are five candidates awaiting approval – compared to seven last year. The decrease is also a result of the successful authorisation of three new drugs.

Germany, FranceGermany

21.12.2011

Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...

GermanyGermany

20.12.2011

Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...

GermanyGermany

16.12.2011

Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...

GermanyGermany

15.12.2011

Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...

GermanyGermany

15.12.2011

While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...

GermanyGermany

08.12.2011

Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...

GermanyGermany

03.11.2011

Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....

GermanyGermany

02.11.2011

Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/1/article/germanys-biotech-sector-grows-despite-financial-crisis.html

Events

All Events

Stock list

All quotes

TOP

  • PHARMING (NL)0.48 EUR11.63%
  • MDX HEALTH (B)3.80 EUR10.79%
  • NEUROVIVE PHARMACEUTICAL AB (S)70.00 SEK8.53%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.46 EUR-10.26%

TOP

  • WILEX (D)2.82 EUR231.8%
  • ADDEX (CH)3.80 CHF58.3%
  • NEUROVIVE PHARMACEUTICAL AB (S)70.00 SEK44.9%

FLOP

  • HYBRIGENICS (F)1.72 EUR-29.5%
  • PROSENSA (NL)9.67 USD-23.8%
  • VITA 34 (D)4.18 EUR-20.4%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)431.00 GBP676.6%
  • PAION (D)2.42 EUR255.9%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.6%
  • CYTOS (CH)0.27 CHF-92.0%
  • THROMBOGENICS (B)9.16 EUR-70.4%

No liability assumed, Date: 30.07.2014


Current issue

All issues

Product of the week

Products